Eli Lilly's growth rate has accelerated significantly in recent years due to its GLP-1 drugs. The stock, however, trades at more than 40 times its trailing earnings. Eli Lilly (NYSE: LLY) has been an ...

The browser you are using is no longer supported on this site. It is highly recommended that you use the latest versions of a supported browser in order to receive an optimal viewing experience. The ...

With shares up 20% over the past 12 months, Eli Lilly appears to have come out on top in the battle to dominate the weight-loss drug market, with rival Novo Nordisk sinking 52% over the same period.

Matthew Herper covers medical innovation — both its promise and its perils. Everything changed with a white envelope. On Dec. 20, 2018, Jacob Van Naarden, the chief operating officer of a biotech ...

Eli Lilly said its next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight. The drug ...

Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are industry leaders. Mounjaro and Zepbound are driving the company’s impressive revenue growth. Investors are well aware of the company's strengths and ...

April 8, 2026: We added one new [DIM 2] Anime Fighting Simulator: Endless code. The current codes offer plenty of yen and additional EXP! If you're hoping to race through the ranks of the return of ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Diabetes patients taking ...

When you picture New England Patriots running backs of the 21st century, you don’t need to think long and hard before reaching a specific archetype: the undersized, jiggly receiving back who has been ...

Eli Lilly (LLY) is down to the $937 area as investors await an April FDA decision on its oral obesity pill, orforglipron. Moreover, shares of Eli Lilly rival Novo Nordisk (NVO) are down 25% year to ...

Eli Lilly is building an insurmountable lead in GLP-1 drugs through superior clinical efficacy of tirzepatide, direct-to-employer distribution that bypasses pharmacy benefit managers, and a ...